Decent Q1; Clarity on US tariff exposure was a key takeaway
16/04/25 -"While Virbac’s Q1 sales slightly missed the street’s estimates, decent growth in both its segments places the firm in a position to meet its full-year guidance, which remains unchanged. ..."
Pages
59
Language
English
Published on
16/04/25
You may also be interested by these reports :
09/05/25
Novonesis delivered a strong start to FY25, with 11% organic revenue growth and a 310bps expansion in adjusted EBITDA margin to 38.3%, both ahead of ...
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...
06/05/25
1:10 share split adjustments – Downgrade to Add (prev.: Buy)
06/05/25
Q1 results met expectations, and strong growth was witnessed across the segments as well as three key molecules. Of note was a rebound in the animal ...